The Past, Present, and Future of 340B Drug Pricing
May 3, 2022
As the 340B Drug Pricing Program reaches its 30th year, its successes and failures have come into sharp relief. Tim Paine, principal consultant at Blue Fin Group, discussed the history, present state, and potential future of the program in a session at this year’s Asembia Specialty Pharmacy Summit. The program was enacted in 1992, as healthcare systems were financially overwhelmed attempting to provide care to underinsured and uninsured patients.
In an article by Gianna Mellilo that summarized the talk, “Offering his take on the program, Paine noted that throughout his career he’s witnessed both sides of the debate—having been employed by both a pharmacy and a manufacturer. ‘The organic growth that’s occurred in [the pharmacy] industry over time, that’s really had a tremendous bearing on this program as we know it,’ Paine said. In addition to growth in the pharmaceutical industry, the increasing number of players in the 340B program—from payers, to pharmacy benefit managers (PBMs) to health systems—has all added to the complexity of 340B in 2022, he added.“
To read more, click here.
(Source: AJMC, May 3rd, 2022)